Forbion European Acquisition Corp. (FRBN)
Price:
21.13 USD
( - -0.36 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
DESCRIPTION
Forbion European Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to identify opportunities in the life sciences industry in Europe. The company was incorporated in 2021 and is based in Wilmington, Delaware.
NEWS
enGene (Nasdaq: ENGN) Launched as Publicly Traded Genetic Medicines Company
prnewswire.com
2023-11-01 07:30:00Business combination transaction completed with Forbion European Acquisition Corp. Clinical stage biotechnology company with EG-70 lead program in pivotal clinical study targeting BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) $138M in gross proceeds from transaction to support advancement of EG-70 clinical program, which is currently enrolling patients, and continued pipeline expansion in additional therapeutic areas BOSTON and MONTREAL, Nov. 1, 2023 /PRNewswire/ - enGene Holdings Inc. ("enGene" or the "Company,") (NASDAQ: ENGN) today announced the completion of the previously announced business combination between enGene Inc., a clinical-stage genetic medicines company whose lead program is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), and Forbion European Acquisition Corp. ("FEAC," Nasdaq: FRBN), a special purpose acquisition company. The Company also announced a concurrent transaction financing.
Why Is Forbion European Acquisition (FRBN) Stock Up 100% Today?
investorplace.com
2023-10-27 15:22:07In general, market sentiment around special purpose acquisition companies (SPACs) has dwindled considerably since 2020-2021. That said, certain SPAC companies continue to see outsized interest.
No data to display
No data to display
enGene (Nasdaq: ENGN) Launched as Publicly Traded Genetic Medicines Company
prnewswire.com
2023-11-01 07:30:00Business combination transaction completed with Forbion European Acquisition Corp. Clinical stage biotechnology company with EG-70 lead program in pivotal clinical study targeting BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) $138M in gross proceeds from transaction to support advancement of EG-70 clinical program, which is currently enrolling patients, and continued pipeline expansion in additional therapeutic areas BOSTON and MONTREAL, Nov. 1, 2023 /PRNewswire/ - enGene Holdings Inc. ("enGene" or the "Company,") (NASDAQ: ENGN) today announced the completion of the previously announced business combination between enGene Inc., a clinical-stage genetic medicines company whose lead program is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), and Forbion European Acquisition Corp. ("FEAC," Nasdaq: FRBN), a special purpose acquisition company. The Company also announced a concurrent transaction financing.
Why Is Forbion European Acquisition (FRBN) Stock Up 100% Today?
investorplace.com
2023-10-27 15:22:07In general, market sentiment around special purpose acquisition companies (SPACs) has dwindled considerably since 2020-2021. That said, certain SPAC companies continue to see outsized interest.